Obsessive-compulsive disorder:: An open-label pilot trial of escitalopram

被引:9
|
作者
Almeida, Amanda Galvao-de
Quarantini, Lucas C.
Gois, Cristianne R.
Santos-Jesus, Rogerio
Miranda-Scippa, Angela M. A.
de Oliveira, Irismar R.
Prado, Helena da Silva
Leckman, James F.
Rosario, Maria C. [1 ]
机构
[1] Univ Fed Bahia, Dept Psychiat, BR-41170290 Salvador, BA, Brazil
[2] Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil
[3] Univ Sao Paulo, Sch Med, Inst Psychiat, OCD Spectrum Disorders Project, BR-05508 Sao Paulo, Brazil
[4] Yale Univ, Sch Med, Childs Study Ctr, New Haven, CT 06520 USA
关键词
D O I
10.1017/S1092852900021258
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: Selective serotonin reuptake inhibitors are considered the most effective and well-established pharmacotherapy for the treatment of obsessive-compulsive disorder (OCD), a chronic and disabling condition. However, similar to 40% of patients do not have a significant improvement, suggesting that new medications are needed. This study was designed to investigate the treatment response to escitalopram in OCD patients. Methods: This open-label study involved 11 adult OCD outpatients diagnosed with the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I Disorders. Data were collected and the treatment response was assessed by an experienced psychiatrist by using the Yale-Brown Obsessive-Compulsive Scale. Subjects received escitalopram 30 mg/day for 12 weeks starting at 10 mg/day. Dosage adjustments were made within 2 weeks, depending on the tolerability of the patient. Results: Six of the 11 patients (54.5%) presented a reduction of at least 40% in the baseline total Yale-Brown Obsessive-Compulsive Scale scores. Conclusion: Despite the small sample size and the open-label nature of this trial, these data suggest that escitalopram may be a useful option for patients with OCD.
引用
收藏
页码:519 / 524
页数:6
相关论文
共 50 条
  • [1] Naltrexone in Obsessive-Compulsive Disorder: an Open-Label Trial
    Hamidi, Aram
    Jahanguiri, Bijan
    Esfahani, Mehdi Nasr
    Dadfar, Mahbuobeh
    [J]. IRANIAN JOURNAL OF PSYCHIATRY AND BEHAVIORAL SCIENCES, 2007, 1 (01) : 16 - 21
  • [2] Open-label trial of paroxetine in children with obsessive-compulsive disorder
    Diler, RS
    Avci, A
    [J]. CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2000, 61 (10): : 706 - 719
  • [3] Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study
    Stryjer, Rafael
    Dambinsky, Yael
    Timinsky, Igor
    Green, Tamar
    Kotler, Moshe
    Weizman, Abraham
    Spivak, Baruch
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2013, 28 (02) : 96 - 98
  • [4] Obsessive-compulsive disorder in the postpartum - Open-label trial of quetiapine augmentation
    Misri, S
    Milis, L
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2004, 24 (06) : 624 - 627
  • [5] Minocycline Augmentation of Pharmacotherapy in Obsessive-Compulsive Disorder: An Open-Label Trial
    Rodriguez, Carolyn I.
    Bender, James, Jr.
    Marcus, Sue M.
    Snape, Michael
    Rynn, Moira
    Simpson, Helen Blair
    [J]. JOURNAL OF CLINICAL PSYCHIATRY, 2010, 71 (09) : 1247 - 1249
  • [6] What is the optimal dose of escitalopram for the treatment of obsessive-compulsive disorder? A naturalistic open-label study
    Shim, Geumsook
    Park, Hye Youn
    Jang, Joon Hwan
    Kim, Euitae
    Park, Hye Yoon
    Hwang, Jae Yeon
    Kim, Sung Nyun
    Jang, Go-Eun
    Kwon, Jun Soo
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2011, 26 (05) : 284 - 290
  • [7] An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder
    Bakhla, Ajay Kumar
    Vijay
    Soren, Subhas
    Sarkhel, Sujit
    Choudhury, Suprakash
    [J]. INDIAN JOURNAL OF PSYCHIATRY, 2013, 55 (05) : S118 - S119
  • [8] Venlafaxine open-label treatment of patients with obsessive-compulsive disorder
    Sevincok, L
    Uygur, B
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2002, 36 (06): : 817 - 817
  • [9] Open-Label Study of Duloxetine for the Treatment of Obsessive-Compulsive Disorder
    Dougherty, Darin D.
    Corse, Andrew K.
    Chou, Tina
    Duffy, Amanda
    Arulpragasam, Amanda R.
    Deckersbach, Thilo
    Jenike, Michael A.
    Keuthen, Nancy J.
    [J]. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (02): : 1 - 4
  • [10] Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
    Coric, V
    Taskiran, S
    Pittenger, C
    Wasylink, S
    Mathalon, DH
    Valentine, G
    Saksa, J
    Wu, YT
    Gueorguieva, R
    Sanacora, R
    Malison, RT
    Krystal, JH
    [J]. BIOLOGICAL PSYCHIATRY, 2005, 58 (05) : 424 - 428